Ultevursen for Vision Impairments
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a drug called ultevursen, which is injected into the eye, for patients with a specific genetic form of Retinitis Pigmentosa. The drug targets and modifies the genetic mutation causing their vision loss.
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, if you are on treatments that affect the immune system or have used investigational drugs recently, you may need to discuss this with the trial team.
What data supports the effectiveness of the treatment Ultevursen for Retinitis Pigmentosa?
Who Is on the Research Team?
Sepul Bio Medical Monitor
Principal Investigator
Sepul Bio
Sepul Bio Clinical Operations Director
Principal Investigator
Sepul Bio
Are You a Good Fit for This Trial?
This trial is for adults and minors with parental consent who have Retinitis Pigmentosa due to USH2A gene mutations. Participants must have a certain level of vision in both eyes, no treatment history with genetic or stem-cell therapy, and not be allergic to the study medication components.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a loading dose of ultevursen on Day 1, followed by maintenance doses at Month 3 and every 6 months thereafter
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ultevursen
Ultevursen is already approved in European Union, United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laboratoires Thea
Lead Sponsor
ProQR Therapeutics
Lead Sponsor
Sepul Bio
Collaborator
Sepul Bio
Industry Sponsor